Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy.

ABSTRACT:

Introduction

Although T-cell immunotherapies have been effective in the treatment of hematological malignancies, solid tumors have proven challenging due to the immunosuppressive microenvironment and lack of viable target antigens. The immune checkpoint ligand CD70, overexpressed in several solid tumors, yet with limited expression in healthy tissue, has emerged as a promising immunotherapeutic target.

Method

This study describes the generation and preclinical characterization of ADP-520, a high-affinity, fratricide-resistant, CD70-targeted T-cell receptor fusion construct (TRuC) T-cell therapy enhanced with constitutively expressed mbIL-15, a membrane-bound fusion protein comprising interleukin-15 (IL-15) linked to full-length IL-15 receptor-alpha. The phenotypic distributi

SUBMITTER: Webb L 

PROVIDER: S-EPMC12162932 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature